Millions of women who missed early HPV vaccination opportunities now face rising cervical cancer rates. New research shows screening rates dropping precisely when they're needed most.

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

P 3, thereby counteracting the actions of PI3Ks. The PI3K pathway is one of the most frequently activated signalling pathways in human cancer. Oncogenic activation of this pathway commonly occurs ...

“Full House” alum Dave Coulier is sharing a health update after being diagnosed with stage 3 non-Hodgkins lymphoma ... in his neck showed “no sign of cancer.” “One of the few times ...

Keep your eyes open and observe each minute detail in both pictures. Time is running out—do you have what it takes? Countdown Begins! Did you manage to find at least one or two differences?

Auto news: This Melbourne suburb doesn't want to fix its potholes. © 2025 Nine Entertainment Co.

Cervical cancer rates are on the rise among younger women, owing in part to a lack of awareness, screening and prevention. A new study found that the percentage of women screened for cervical ...

The positive impact of the HPV vaccination is also starting to be seen in reduced cervical cancer incidence rates among vaccinated women (see the reduced incidence rate in 2020 for women aged 25 – 29 ...

(AP Photo/Alberto Pezzali, File) Britain’s King Charles III holds up flowers he was given as he leaves after a visit to University College Hospital Macmillan Cancer Centre in London, Tuesday, April 30 ...

King Charles III spent a short time under observation in hospital on Thursday after experiencing side effects from treatment for cancer, Buckingham Palace said. The king has been undergoing ...

King Charles III is recovering after an unexpected hospital stay. The British monarch was briefly hospitalized March 27 after a routine appointment amid his cancer battle, resulting in a last ...

Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve overall survival (OS) in platinum-resistant ovarian cancer (PROC ...